Andrew D. Blann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andrew D. Blann has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Gregory Yoke Hong Lip
Liverpool Centre of Cardiovascular Science at University of Liverpool Liverpool John Moores University and Liverpool Heart & Chest Hospital Liverpool UK
2 shared publications - Rebekka Heitmar
Centre for Vision across the Life Span (CVLS), School of Applied Sciences, University of Huddersfield, Huddersfield, UK
2 shared publications Y. C. Lau
University of Birmingham Institute for Cardiovascular Sciences, City Hospital, Birmingham, B18 7QH, UK
2 shared publicationsA Ashry
Assiut University
1 shared publicationA. A. Ashry
Departments of Cardiothoracic Surgery Assiut University, Assiut, Egypt
1 shared publicationAa Meki
Assiut University
1 shared publication
Latest Publications
- Open Access
- 22 May 2026
- Published by Frontiers Media SA in British Journal of Biomedical Science
- Vol. 83, 14743
The Molecular Pathology of Non-Malignant Haematological Disease
In almost all aspects of biomedical science, molecular pathology has brought unprecedented value in the diagnosis and management of human disease. Numerous commentators cite haematological disease as the leading genetic cause of global mortality and morbidity, and of these, those of the red blood cells are the most frequent. This narrative review, with a historical perspective, will discuss the role of genetics in these conditions, the leading pathology of red blood cells being the haemoglobinopathies, principally sickle cell disease and thalassaemia, with their many variants, and with potential roles for non-coding RNAs. The impact of genetics into conditions of the red cell cytoplasm will consider the enzymopathies, led by glucose-6-phosphate dehydrogenase deficiency, and extend to those of the cell membrane, causing disease such as hereditary elliptocytosis. Mutations in genes coding almost all the coagulation factors, and several platelet abnormalities, are discussed, as are those linked to conditions of iron overload. Previous, current and evolving technologies for diagnostic testing and their link with potential targeted therapeutic options for patient management are considered.
- 22 May 2026
- Published by Frontiers Media SA in British Journal of Biomedical Science
- Vol. 83, 14743
Open AccessThe Molecular Pathology of Non-Malignant Haematological Disease
In almost all aspects of biomedical science, molecular pathology has brought unprecedented value in the diagnosis and management of human disease. Numerous commentators cite haematological disease as the leading genetic cause of global mortality and morbidity, and of these, those of the red blood cells are the most frequent. This narrative review, with a historical perspective, will discuss the role of genetics in these conditions, the leading pathology of red blood cells being the haemoglobinopathies, principally sickle cell disease and thalassaemia, with their many variants, and with potential roles for non-coding RNAs. The impact of genetics into conditions of the red cell cytoplasm will consider the enzymopathies, led by glucose-6-phosphate dehydrogenase deficiency, and extend to those of the cell membrane, causing disease such as hereditary elliptocytosis. Mutations in genes coding almost all the coagulation factors, and several platelet abnormalities, are discussed, as are those linked to conditions of iron overload. Previous, current and evolving technologies for diagnostic testing and their link with potential targeted therapeutic options for patient management are considered.
- Open Access
- 31 July 2023
- Published by Springer Nature in Research Square
A pilot study of increased gene expression of Growth Differentiation Factor 15 and Telomerase Reverse Transcriptase in the middle-aged with acute coronary artery disease
Introduction: Growth Differentiation Factor 15 (GDF15) and Telomerase Reverse Transcriptase (TERT) may have roles as serum biomarkers of the pathophysiology of cardiovascular disease. We hypothesised altered genomic expression of the genes for these molecules in middle aged subjects with acute coronary artery disease. Method: Venous blood was obtained from 53 patients (27 with diabetes) presenting with an acute coronary syndrome and subsequently shown to have coronary artery disease (CAD), and from 46 age and sex matched controls free of cardiovascular disease and its risk factors. Relative expression of leukocyte transcriptome GAPDH, GDF15and TERT were determined by RT-PCR and quantified by quantitation-comparative Ct (ΔΔCt). Results: Compared to expression in controls, mean (95% confidence interval) relative expression of GDF15in the patients was 1.38 (1.13-1.49) (pTERT was 1.12 (1.04-1.20) p=0.003), with relative expression of GDF15 being greater than that of TERT (pGDF15 in 26 patients free of diabetes (1.6 [1.42-1.78]) compared to those 27 with diabetes (1.6 [1.29-1.91]) (p=0.996). Similarly, there was no difference in the expression of TERT in patients free of diabetes (1.19 [1.06-1.33]) compared to those with diabetes (1.25 [0.98-1.50]) (p=0.739). Conclusion: Relative expression of GDF15 and TERTare both increased in middle-aged patients with CAD and in CAD+diabetes, with no difference between the patient groups. These genes may have roles in the pathogenesis of acute coronary artery disease.
- 31 July 2023
- Published by Springer Nature in Research Square
Open AccessA pilot study of increased gene expression of Growth Differentiation Factor 15 and Telomerase Reverse Transcriptase in the middle-aged with acute coronary artery disease
Introduction: Growth Differentiation Factor 15 (GDF15) and Telomerase Reverse Transcriptase (TERT) may have roles as serum biomarkers of the pathophysiology of cardiovascular disease. We hypothesised altered genomic expression of the genes for these molecules in middle aged subjects with acute coronary artery disease. Method: Venous blood was obtained from 53 patients (27 with diabetes) presenting with an acute coronary syndrome and subsequently shown to have coronary artery disease (CAD), and from 46 age and sex matched controls free of cardiovascular disease and its risk factors. Relative expression of leukocyte transcriptome GAPDH, GDF15and TERT were determined by RT-PCR and quantified by quantitation-comparative Ct (ΔΔCt). Results: Compared to expression in controls, mean (95% confidence interval) relative expression of GDF15in the patients was 1.38 (1.13-1.49) (pTERT was 1.12 (1.04-1.20) p=0.003), with relative expression of GDF15 being greater than that of TERT (pGDF15 in 26 patients free of diabetes (1.6 [1.42-1.78]) compared to those 27 with diabetes (1.6 [1.29-1.91]) (p=0.996). Similarly, there was no difference in the expression of TERT in patients free of diabetes (1.19 [1.06-1.33]) compared to those with diabetes (1.25 [0.98-1.50]) (p=0.739). Conclusion: Relative expression of GDF15 and TERTare both increased in middle-aged patients with CAD and in CAD+diabetes, with no difference between the patient groups. These genes may have roles in the pathogenesis of acute coronary artery disease.
- Open Access
- 26 April 2017
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 16 (1) , 1-10
Retinal vessel diameters and reactivity in diabetes mellitus and/or cardiovascular disease
Retinal vessel calibre and vascular dilation/constriction in response to flicker light provocation may provide a measure distinguishing patients suffering from diabetes mellitus and/or cardiovascular disease. One hundred and sixteen age and sex matched patients with diabetes mellitus (DM), cardiovascular disease (CVD) and both DM and CVD (DM + CVD) underwent systemic and intraocular pressure measurements. Retinal vessel calibres were assessed using a validated computer-based program to compute central retinal artery and vein equivalents (CRVE) from monochromatic retinal images. Vessel dilation and constriction responses to flicker light provocation were assessed by continuous retinal vessel diameter recordings. Plasma endothelial markers von Willebrand factor (vWf) and soluble E selectin (sEsel) were measured by ELISA. Retinal vessel calibres were comparable across groups but CRVE correlated significantly with disease duration in DM patients (r = 0.57, p < 0.001). Patients suffering DM only exhibited reduced arterial vasomotion at rest and reduced arterial constriction following flicker light induced vessel dilation compared to patients with CVD and those suffering both CVD + DM (p = 0.030). Patients suffering from CVD + DM exhibited significant differences between each flicker cycle in regards to arterial maximum constriction (p = 0.006) and time needed to reach arterial maximum dilation (p = 0.004), whereas the other two groups did not show such inconsistencies between individual flicker cycles. vWf was raised in CVD + DM compared to the other two groups (p ≤ 0.02), whilst sEsel was raised in CVD + DM compared to DM alone (p = 0.044). Dynamic retinal vascular calibres as obtained by continuous diameter measurements using flicker light provocation can reveal subtle differences between groups suffering from CVD with and without DM. This difference in reaction pattern and lack of arterial constriction in DM may provide a suitable marker to monitor progression.
- 26 April 2017
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 16 (1) , 1-10
Open AccessRetinal vessel diameters and reactivity in diabetes mellitus and/or cardiovascular disease
Retinal vessel calibre and vascular dilation/constriction in response to flicker light provocation may provide a measure distinguishing patients suffering from diabetes mellitus and/or cardiovascular disease. One hundred and sixteen age and sex matched patients with diabetes mellitus (DM), cardiovascular disease (CVD) and both DM and CVD (DM + CVD) underwent systemic and intraocular pressure measurements. Retinal vessel calibres were assessed using a validated computer-based program to compute central retinal artery and vein equivalents (CRVE) from monochromatic retinal images. Vessel dilation and constriction responses to flicker light provocation were assessed by continuous retinal vessel diameter recordings. Plasma endothelial markers von Willebrand factor (vWf) and soluble E selectin (sEsel) were measured by ELISA. Retinal vessel calibres were comparable across groups but CRVE correlated significantly with disease duration in DM patients (r = 0.57, p < 0.001). Patients suffering DM only exhibited reduced arterial vasomotion at rest and reduced arterial constriction following flicker light induced vessel dilation compared to patients with CVD and those suffering both CVD + DM (p = 0.030). Patients suffering from CVD + DM exhibited significant differences between each flicker cycle in regards to arterial maximum constriction (p = 0.006) and time needed to reach arterial maximum dilation (p = 0.004), whereas the other two groups did not show such inconsistencies between individual flicker cycles. vWf was raised in CVD + DM compared to the other two groups (p ≤ 0.02), whilst sEsel was raised in CVD + DM compared to DM alone (p = 0.044). Dynamic retinal vascular calibres as obtained by continuous diameter measurements using flicker light provocation can reveal subtle differences between groups suffering from CVD with and without DM. This difference in reaction pattern and lack of arterial constriction in DM may provide a suitable marker to monitor progression.
- Open Access
- 23 August 2016
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 42 (4) , 535-544
Effects of non-vitamin K antagonist oral anticoagulants on fibrin clot and whole blood clot formation, integrity and thrombolysis in patients with atrial fibrillation
Non-vitamin K antagonist oral anticoagulants (NOACs) are replacing warfarin and heparins in several clinical situations. With varying modes of action, the effects of NOACs on thrombus formation, integrity, and lysis is unknown. To determine whether two techniques of thrombelastography (TEG) and a micro-plate assay (MPA) provide novel data on thrombus formation, integrity and lysis in those taking a NOACs compared to warfarin and a control group taking aspirin. We assessed thrombogenesis, clot integrity and fibrinolysis in blood (TEG) and plasma (MPA) from 182 atrial fibrillation patients—50 on aspirin, 50 on warfarin, and 82 on a NOAC (17 apixaban, 19 dabigatran and 46 rivaroxaban). Eleven of 16 TEG indices and 4 of 5 MPA indices differed (p ≤ 0.01) between those on aspirin, warfarin or a NOAC. Three TEG indices and 4 MPA indices differed (p < 0.01) between the NOACs. Time to initiation of clot formation was most rapid on apixaban, then rivaroxaban and slowest on dabigatran. The rate of clot formation was most rapid on dabigatran, then apixaban, and slowest on rivaroxaban. Clot density was greatest on rivaroxaban, then apixaban, but weakest on dabigatran. The rate of clot dissolution was most rapid in apixaban, then dabigatran, and slowest on rivaroxaban. The TEG and MPA identify major differences in thrombogenesis and fibrinolysis in different NOACs. These techniques may have value in investigating the effects of these drugs on haemostasis in a clinical setting, and in identifying those in need of targeted therapy.
- 23 August 2016
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 42 (4) , 535-544
Open AccessEffects of non-vitamin K antagonist oral anticoagulants on fibrin clot and whole blood clot formation, integrity and thrombolysis in patients with atrial fibrillation
Non-vitamin K antagonist oral anticoagulants (NOACs) are replacing warfarin and heparins in several clinical situations. With varying modes of action, the effects of NOACs on thrombus formation, integrity, and lysis is unknown. To determine whether two techniques of thrombelastography (TEG) and a micro-plate assay (MPA) provide novel data on thrombus formation, integrity and lysis in those taking a NOACs compared to warfarin and a control group taking aspirin. We assessed thrombogenesis, clot integrity and fibrinolysis in blood (TEG) and plasma (MPA) from 182 atrial fibrillation patients—50 on aspirin, 50 on warfarin, and 82 on a NOAC (17 apixaban, 19 dabigatran and 46 rivaroxaban). Eleven of 16 TEG indices and 4 of 5 MPA indices differed (p ≤ 0.01) between those on aspirin, warfarin or a NOAC. Three TEG indices and 4 MPA indices differed (p < 0.01) between the NOACs. Time to initiation of clot formation was most rapid on apixaban, then rivaroxaban and slowest on dabigatran. The rate of clot formation was most rapid on dabigatran, then apixaban, and slowest on rivaroxaban. Clot density was greatest on rivaroxaban, then apixaban, but weakest on dabigatran. The rate of clot dissolution was most rapid in apixaban, then dabigatran, and slowest on rivaroxaban. The TEG and MPA identify major differences in thrombogenesis and fibrinolysis in different NOACs. These techniques may have value in investigating the effects of these drugs on haemostasis in a clinical setting, and in identifying those in need of targeted therapy.
- Open Access
- 20 July 2016
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 254 (11) , 2257-2265
The relationship of systemic markers of renal function and vascular function with retinal blood vessel responses
To test the hypothesis of a significant relationship between systemic markers of renal and vascular function (processes linked to cardiovascular disease and its development) and retinal microvascular function in diabetes and/or cardiovascular disease.
- 20 July 2016
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 254 (11) , 2257-2265
Open AccessThe relationship of systemic markers of renal function and vascular function with retinal blood vessel responses
To test the hypothesis of a significant relationship between systemic markers of renal and vascular function (processes linked to cardiovascular disease and its development) and retinal microvascular function in diabetes and/or cardiovascular disease.
- 4 April 2016
- Published by Taylor & Francis in Annals of Medicine
- Vol. 48 (4) , 275-281
Effect of renal function on whole blood and fibrin clot formation in atrial fibrillation patients on warfarin
Objective: Atrial fibrillation (AF) brings a risk of thrombosis, requiring oral coagulation, and is associated with renal impairment. The two processes may be linked, as altered fibrin clot structure is present in end-stage renal failure. We hypothesised that progressively deteriorating renal function is linked to altered whole blood and fibrin clot properties and fibrinolysis. Methods: Thrombogenesis and fibrinolysis in 200 warfarinised AF patients was assessed by thromboelastography (TEG), a micro-plate assay (MPA) and the international normalized ratio (INR). Renal function was determined by creatinine clearance and two versions of the estimated glomerular filtration rate (eGFR). Results: Two TEG indices independently reflecting thrombogenesis were linked to creatinine clearance (p < 0.01), whilst a third, reflecting clot strength, was linked to the eGFR (p < 0.001). MPA indices of thrombogenesis and clot density (p < 0.001), and an index of fibrinolysis (p < 0.001) were linked to the eGFR. The time for 50% of the fibrin clot to lyse was linked to creatinine clearance (p = 0.001). The INR was unrelated to any renal function index, and the CHA2DS2VASc score was unrelated to any index. Conclusion: In warfarinised AF patients, renal function is linked to whole blood clot and fibrin clot formation, structure and dissolution, but has no effect on the INR.
- 4 April 2016
- Published by Taylor & Francis in Annals of Medicine
- Vol. 48 (4) , 275-281
Effect of renal function on whole blood and fibrin clot formation in atrial fibrillation patients on warfarin
Objective: Atrial fibrillation (AF) brings a risk of thrombosis, requiring oral coagulation, and is associated with renal impairment. The two processes may be linked, as altered fibrin clot structure is present in end-stage renal failure. We hypothesised that progressively deteriorating renal function is linked to altered whole blood and fibrin clot properties and fibrinolysis. Methods: Thrombogenesis and fibrinolysis in 200 warfarinised AF patients was assessed by thromboelastography (TEG), a micro-plate assay (MPA) and the international normalized ratio (INR). Renal function was determined by creatinine clearance and two versions of the estimated glomerular filtration rate (eGFR). Results: Two TEG indices independently reflecting thrombogenesis were linked to creatinine clearance (p < 0.01), whilst a third, reflecting clot strength, was linked to the eGFR (p < 0.001). MPA indices of thrombogenesis and clot density (p < 0.001), and an index of fibrinolysis (p < 0.001) were linked to the eGFR. The time for 50% of the fibrin clot to lyse was linked to creatinine clearance (p = 0.001). The INR was unrelated to any renal function index, and the CHA2DS2VASc score was unrelated to any index. Conclusion: In warfarinised AF patients, renal function is linked to whole blood clot and fibrin clot formation, structure and dissolution, but has no effect on the INR.
- Open Access
- 4 March 2016
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 42 (2) , 233-244
Laboratory assessment of anti-thrombotic therapy in heart failure, atrial fibrillation and coronary artery disease: insights using thrombelastography and a micro-titre plate assay of thrombogenesis and fibrinolysis
As heart failure, coronary artery disease and atrial fibrillation all bring a risk of thrombosis, anti-thrombotic therapy is recommended. Despite such treatment, major cardiovascular events such as myocardial infarction and stroke still occur, implying inadequate suppression of thrombus formation. Accordingly, identification of patients whose haemostasis remains unimpaired by treatment is valuable. We compared indices for assessing thrombogenesis and fibrinolysis by two different techniques in patients on different anti-thrombotic agents, i.e. aspirin or warfarin. We determined fibrin clot formation and fibrinolysis by a microplate assay and thromboelastography, and platelet marker soluble P selectin in 181 patients with acute or chronic heart failure, coronary artery disease who were taking either aspirin or warfarin. Five thromboelastograph indices and four microplate assay indices were different on aspirin versus warfarin (p < 0.05). In multivariate regression analysis, only microplate assay indices rate of clot formation and rate of clot dissolution were independently related to aspirin or warfarin use (p ≤ 0.001). Five microplate assay indices, but no thrombelastograph index, were different (p < 0.001) in aspirin users. Three microplate assay indices were different (p ≤ 0.002) in warfarin users. The microplate assay indices of lag time and rate of clot formation were abnormal in chronic heart failure patients on aspirin, suggesting increased risk of thrombosis despite anti-platelet use. Soluble P selectin was lower in patients on aspirin (p = 0.0175) but failed to correlate with any other index of haemostasis. The microplate assay shows promise as a tool for dissecting thrombogenesis and fibrinolysis in cardiovascular disease, and the impact of antithrombotic therapy. Prospective studies are required to determine a role in predicting thrombotic risk.
- 4 March 2016
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 42 (2) , 233-244
Open AccessLaboratory assessment of anti-thrombotic therapy in heart failure, atrial fibrillation and coronary artery disease: insights using thrombelastography and a micro-titre plate assay of thrombogenesis and fibrinolysis
As heart failure, coronary artery disease and atrial fibrillation all bring a risk of thrombosis, anti-thrombotic therapy is recommended. Despite such treatment, major cardiovascular events such as myocardial infarction and stroke still occur, implying inadequate suppression of thrombus formation. Accordingly, identification of patients whose haemostasis remains unimpaired by treatment is valuable. We compared indices for assessing thrombogenesis and fibrinolysis by two different techniques in patients on different anti-thrombotic agents, i.e. aspirin or warfarin. We determined fibrin clot formation and fibrinolysis by a microplate assay and thromboelastography, and platelet marker soluble P selectin in 181 patients with acute or chronic heart failure, coronary artery disease who were taking either aspirin or warfarin. Five thromboelastograph indices and four microplate assay indices were different on aspirin versus warfarin (p < 0.05). In multivariate regression analysis, only microplate assay indices rate of clot formation and rate of clot dissolution were independently related to aspirin or warfarin use (p ≤ 0.001). Five microplate assay indices, but no thrombelastograph index, were different (p < 0.001) in aspirin users. Three microplate assay indices were different (p ≤ 0.002) in warfarin users. The microplate assay indices of lag time and rate of clot formation were abnormal in chronic heart failure patients on aspirin, suggesting increased risk of thrombosis despite anti-platelet use. Soluble P selectin was lower in patients on aspirin (p = 0.0175) but failed to correlate with any other index of haemostasis. The microplate assay shows promise as a tool for dissecting thrombogenesis and fibrinolysis in cardiovascular disease, and the impact of antithrombotic therapy. Prospective studies are required to determine a role in predicting thrombotic risk.
- 4 January 2015
- Published by Frontiers Media SA in British Journal of Biomedical Science
- Vol. 72 (3) , 93-101
Effects of propofol and isoflurane on haemodynamics and the inflammatory response in cardiopulmonary bypass surgery
Cardiopulmonary bypass (CPB) causes reperfusion injury that when most severe is clinically manifested as a systemic inflammatory response syndrome. The anaesthetic propofol may have anti-inflammatory properties that may reduce such a response. We hypothesised differing effects of propofol and isoflurane on inflammatory markers in patients having CBP. Forty patients undergoing elective CPB were randomised to receive either propofol or isoflurane for maintenance of anaesthesia. CRP IL-6, IL-8, HIF-1α (ELISA), CD11 and CD18 expression (flow cytometry), and haemoxygenase (HO-1) promoter polymorphisms (PCR/electrophoresis) were measured before anaesthetic induction, 4 hours post-CPB, and 24 hours later. There were no differences in the 4 hours changes in CRP IL-6, IL-8 or CD18 between the two groups, but those in the propofol group had higher HIF-1α (P=0.016) and lower CD11 expression (P=0.026). After 24 hours, compared to the isoflurane group, the propofol group had significantly lower levels of CRP (P<0.001), IL-6 (PPP=0.009) and CD18 (P=0.002) expression. After 24 hours, patients on propofol had increased expression of shorter HO-1 GT(n) repeats than patients on isoflurane (P=0.001). Use of propofol in CPB is associated with a less adverse inflammatory profile than is isofluorane, and an increased up-regulation of HO-1. This supports the hypothesis that propofol has anti-inflammatory activity.
- 4 January 2015
- Published by Frontiers Media SA in British Journal of Biomedical Science
- Vol. 72 (3) , 93-101
Effects of propofol and isoflurane on haemodynamics and the inflammatory response in cardiopulmonary bypass surgery
Cardiopulmonary bypass (CPB) causes reperfusion injury that when most severe is clinically manifested as a systemic inflammatory response syndrome. The anaesthetic propofol may have anti-inflammatory properties that may reduce such a response. We hypothesised differing effects of propofol and isoflurane on inflammatory markers in patients having CBP. Forty patients undergoing elective CPB were randomised to receive either propofol or isoflurane for maintenance of anaesthesia. CRP IL-6, IL-8, HIF-1α (ELISA), CD11 and CD18 expression (flow cytometry), and haemoxygenase (HO-1) promoter polymorphisms (PCR/electrophoresis) were measured before anaesthetic induction, 4 hours post-CPB, and 24 hours later. There were no differences in the 4 hours changes in CRP IL-6, IL-8 or CD18 between the two groups, but those in the propofol group had higher HIF-1α (P=0.016) and lower CD11 expression (P=0.026). After 24 hours, compared to the isoflurane group, the propofol group had significantly lower levels of CRP (P<0.001), IL-6 (PPP=0.009) and CD18 (P=0.002) expression. After 24 hours, patients on propofol had increased expression of shorter HO-1 GT(n) repeats than patients on isoflurane (P=0.001). Use of propofol in CPB is associated with a less adverse inflammatory profile than is isofluorane, and an increased up-regulation of HO-1. This supports the hypothesis that propofol has anti-inflammatory activity.